PhoreMost Secures $50M in Series B Funding to Revolutionize Drug Discovery

PhoreMost, the innovative drug discovery company headquartered in Cambridge, UK, is thrilled to announce its successful fundraising initiative, raising an impressive £50 million. This significant investment marks a pivotal moment for the company as it seeks to revolutionize the pharmaceutical landscape by 'Drugging the Undruggable®' disease targets. At the forefront of this endeavor is the proprietary SITESEEKER® technology, which utilizes advanced PROTEINi® libraries to identify novel therapeutic targets and elucidate effective drugging strategies. The funding will be utilized to expand PhoreMost's extensive pipeline of drug discovery programs, tailored specifically to tackle a range of complex diseases, including various forms of cancer. With this capital injection, the company aims to expedite the development of targeted therapies that not only represent diverse options for patients but also prioritize affordability, ensuring that breakthroughs in medicine are accessible to those in need. Emphasizing collaboration, PhoreMost is committed to fostering partnerships across academia and the pharmaceutical industry to leverage shared expertise for greater advancements in drug development. The company is also dedicated to its community and the environment, actively promoting initiatives like PhoreAll and PhorEST to encourage inclusivity and sustainability in the field. This funding announcement highlights PhoreMost's unwavering commitment to transforming the future of drug discovery and delivering impactful health solutions more efficiently. Interested parties are encouraged to visit PhoreMost’s website to learn more about our groundbreaking research and partnership opportunities: https://www.phoremost.com/contact.